Lifecore Biomedical (Lifecore Biomedical) LT-Debt-to-Total-Asset : 0.44 (As of May. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Lifecore Biomedical's long-term debt to total assests ratio for the quarter that ended in May. 2023 was 0.44.

Lifecore Biomedical's long-term debt to total assets ratio increased from May. 2022 (0.03) to May. 2023 (0.44). It may suggest that Lifecore Biomedical is progressively becoming more dependent on debt to grow their business.

Lifecore Biomedical LT-Debt-to-Total-Asset Historical Data

The historical data trend for Lifecore Biomedical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical LT-Debt-to-Total-Asset Chart

Lifecore Biomedical Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

May23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.18

0.24

0.37

0.03

0.44

Lifecore Biomedical Quarterly Data
	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.37	0.03	0.53	0.44

Lifecore Biomedical LT-Debt-to-Total-Asset Calculation

Lifecore Biomedical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in May. 2023 is calculated as

LT Debt to Total Assets (A: May. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: May. 2023 )	/	Total Assets (A: May. 2023 )
	=	110.774	/	253.545
	=	0.44

Lifecore Biomedical's Long-Term Debt to Total Asset Ratio for the quarter that ended in May. 2023 is calculated as

LT Debt to Total Assets (Q: May. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: May. 2023 )	/	Total Assets (Q: May. 2023 )
	=	110.774	/	253.545
	=	0.44

Lifecore Biomedical (NAS:LFCR) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Lifecore Biomedical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Lifecore Biomedical (Lifecore Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

3515 Lyman Boulevard, Chaska, MN, USA, 55318

Website

https://www.lifecore.com

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.

Executives

Raymond T. White	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc	director	12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper	director	12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway	director	C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I	10 percent owner	450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian	director	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter	director	C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg	officer: Chief Financial Officer	C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles	director	CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall	officer: Executive Vice President	3515 LYMAN BLVD., CHASKA MN 55318